| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
MedSym is a Tuscaloosa, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PeriGen, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Recipharm was established in Sweden in 1995 and has since grown to become a leading Contract Development and Manufacturing Organisation (CDMO). Headquartered in Stockholm, we employ nearly 5 000 people and the Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. For over 20 years we have focussed on supporting pharmaceutical companies in taking their products from early development through to commercial manufacturing. Throughout the entire product lifecycle, we are there for our clients. Time and time again, we have delivered innovative solutions.
Medical Resources is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.